Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Aromatase inhibitors in breast cancer

Hiscox, Stephen Edward ORCID:, Davies, Eleri-Lloyd and Barrett-Lee, Peter 2009. Aromatase inhibitors in breast cancer. Maturitas 63 (4) , pp. 275-279. 10.1016/j.maturitas.2009.05.008

Full text not available from this repository.


Estrogens play important roles in breast cancer development and progression. In postmenopausal women, traditional endocrine therapies such as tamoxifen have sought to inhibit estrogen action by targeting the estrogen receptor itself. However, newer treatments are evolving that target estrogen production in postmenopausal tissues through inhibition of the aromatase enzyme. Clinical data demonstrate that these aromatase inhibitors are superior to tamoxifen as adjuvant therapy for breast cancer and have now replaced tamoxifen as first line therapy in a number of treatment regimens for postmenopausal breast cancer patients.

Item Type: Article
Status: Published
Schools: Pharmacy
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: Aromatase inhibitors; SERM; Tamoxifen; Aromatase; Estrogen
Publisher: Elsevier
ISSN: 0378-5122
Last Modified: 17 Oct 2022 10:01

Citation Data

Cited 37 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item